Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003

August 8, 2003
By Centers for Disease Control and Prevention (U.S.) ...
Source: MMWR. Morbidity and mortality weekly report. 2003; 52(31):735-9.

[PDF-260.70 KB]

English

Details You May Also Like

Details:

Corporate Authors:

Centers for Disease Control and Prevention (U.S.) ; American Thoracic Society.

Centers for Disease Control and Prevention (U.S.) ; American Thoracic Society. Less -
Description:

A previously published report provided guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis (TB). Protease inhibitors and NNRTIs are antiretroviral agents that are substrates that may inhibit or induce cytochrome P-450 isoenzymes (CYP450). Rifamycins are antituberculosis agents that induce CYP450 and may decrease substantially blood levels of the antiretroviral drugs. The pharmacologic interactions are called drug-drug because, in addition to the effect rifamycins have on protease inhibitors and NNRTIs, the antiretroviral agents may affect the blood levels of rifamycins. This notice presents updated data pertaining to drug-drug interactions between these agents and recommendations for their use from a group of CDC scientists and outside expert consultants.
Subjects:

[+]

Antitubercular Agents Drug-Induced Liver Injury Drug Therapy, Combination Humans Pyrazinamide Retrospective Studies Rifampin Tuberculosis
Source:

MMWR. Morbidity and mortality weekly report. 2003; 52(31):735-9.
Pubmed ID:

12904741
Document Type:

Journal Article
Place as Subject:

United States
Volume:

52
Issue:

31
Collection(s):

Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR) Guidelines and Recommendations
Main Document Checksum:

[+]

urn:sha256:3c6fc853388ead287f245a89ef689ec9f5759503635789d079d3901f44844ab8
Download URL:

https://stacks.cdc.gov/view/cdc/7296/cdc_7296_DS1.pdf
File Type:

No Additional Files

More +

Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003

Details:

Supporting Files

You May Also Like